Summary
CVS Health Corporation has reached a settlement with the U.S. Attorney's Office for the Middle District of Florida and the U.S. Drug Enforcement Administration (DEA) for $22 million to resolve allegations concerning the dispensing of controlled substances in Florida. This settlement addresses all civil matters between CVS Health and the DEA within the state. Importantly for investors, the company states that this $22 million payment has already been fully accrued for in prior fiscal periods. This means the settlement payment will not impact current or future earnings beyond what has already been accounted for.
Key Highlights
- 1CVS Health settled with the U.S. Attorney's Office and DEA for $22 million.
- 2The settlement resolves allegations related to dispensing controlled substances in Florida.
- 3The agreement covers all civil matters between CVS Health and the DEA in Florida.
- 4The $22 million payment has been fully accrued in prior fiscal periods.
- 5This means the settlement does not represent a new financial impact on current earnings.
- 6The information is furnished under Regulation FD and not filed, meaning it won't be incorporated into future registration statements automatically.